Form 8-K Coeptis Therapeutics For: Jan 31
- Futures rise as focus shifts to Fed after banks see relief
- Amazon to cut 9,000 jobs at AWS, advertising, Twitch and PXT; analysts positive
- European bank shares rally, bonds battered after Credit Suisse debt wipeout
- Oil rises as banking fears ease for now
- Banking stocks steady after Credit Suisse rescue as focus turns to Fed, US banks
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
|(Address of principal executive offices)||(Zip Code)|
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||
Name of each exchange
on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 8.01 Other Events
On January 31, 2023, Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis”) issued a press release announcing the execution of a sponsored research agreement with University of Pittsburgh related to the advancement of the pre-clinical development of SNAP-CAR T cells targeting HER2 as well as identify opportunities to expand the applicability of SNAP-CAR. As previously disclosed by Coeptis, SNAP-CAR is a multi-antigen chimeric antigen receptor T cell (CAR T) technology that was previously licensed by Coeptis from the University of Pittsburgh. A copy of the press release is included with the Current Report on Form 8-K.
|Item 9.01||Financial Statements and Exhibits.|
|99.1||Press Release, dated January 31, 2023|
|104||Cover Page Interactive Data File (formatted in iXBRL)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Coeptis Therapeutics Holdings, Inc.|
|Date: January 31, 2023||By:||/s/ David Mehalick|
Chief Executive Officer
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calibre Continues to Expand the New High-Grade Gold Discovery at Panteon North & Along the Multi-Kilometre VTEM Gold Corridor; Additional Drilling Intersects 17.45 g/t Gold Over 4.1 Metres Following U
- Form 8.3 - [DEVRO PLC 20 03 2023] - (CGWL)
- Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!